Bioxodes SA: Valuation, Funding & Investors
A clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. The company’s lead asset, BIOX-101, is a first-in-class drug candidate being developed to treat stroke, with a unique dual mechanism of action forming the foundation of an innovative pipeline for thromboinflammatory diseases.
Leadership & Board
- Current Number of Employees
- 12
- Current LinkedIn Followers
- 2,805
Latest Estimated Valuation
- Total Amount Raised
- $6M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $6M
- Latest Funding Round
- Series A
Company Momentum
PositiveBioxodes SA LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Bioxodes SA had 12 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Bioxodes SA had 2,805 followers as of November 2, 2026. The number of followers increased by 11 (0.39%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 10, 2025 | Series A | $5.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Newton Biocapital | Series A |
Similar Companies
A snapshot of private companies similar to Bioxodes SA, helping you discover and navigate related company profiles.
Related News and Analysis
